NEW YORK (GenomeWeb) – Meridian Bioscience said after the close of the market on Monday that its preliminary fiscal first quarter revenues are expected to be down about 2 percent year over year.

For fiscal Q1 2019, the company said that revenues are anticipated to be in the range of $51 million to $51.5 million compared to $52.3 million a year ago. The analysts' average estimate is $53.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.